Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| NT Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed | |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50M | Series A | Biotech, Healthtech | United States | Investors | |
| MT Develops therapies to halt fibrosis in multiple organ systems | $76M | Series B | Biotech | United States | Investors | |
| PS Provides AI-native due diligence for life sciences dealmaking | $20M | Series A | Biotech | United States | Investors | |
| RM Rakuten MedicalCompany profile Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment | $100M | Series FSeries C+ | Biotech | United States | Investors | |
| CH Corsera HealthCompany profile Develops preventive RNAi medicines for cardiovascular disease prediction and prevention Develops preventive RNAi medicines for cardiovascular disease prediction and prevention | $80M | Series A | Biotech, Healthtech | United States | Investors | |
| ST Uses cells as sensors to uncover first-in-class medicines | $200M | Series CSeries C+ | Biotech | United States | Investors | |
| B BiographicaCompany profile Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience | £7M | Undisclosed | Biotech, Agritech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.